

## Granules India enters CDMO business by acquiring Senn Chemicals AG for Rs 192.5 Cr

22 February 2025 | News

## Granules aim to become a key player in development and manufacturing of peptide-based applications across Pharmaceuticals



Hyderabad-based Granules India has announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specialising in peptides. Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services. The closing of the acquisition, at the cost of Rs 192.5 crore, is subject to certain conditions. The closing is expected to occur in the first half of 2025.

The acquisition brings Senn's expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments.

This enables Granules' acquiring capabilities into high-growth peptide- based therapeutics. The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn's R&D capabilities.

The acquisition marks Granules foray into CDMO segments, leveraging Senn's existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn's European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules' global footprint.